Peplin Initiates Phase 3 Clinical Trials with PEP005 Gel in AK on Face and Scalp read more
Peplin's Positive Phase II AK Trial Results Published in JAAD read more
Positive Results for Peplin's First Phase III AK Trial read more
Peplin Results for the Quarter Ended 31 March 2009 read more
A. The shareholder-approved restructure of Peplin will enable the Peplin group to achieve its strategic goals as it is expected to:
A. You will need to complete and return a form. See the Shareholder services page for instructions and forms.
A. Peplin's shares have been listed on the Australian Securities Exchange (ASX) since September 2000. Peplin shares trade as CDIs (or CHESS Depositary Interests) under the symbol PLI.AX after a shareholder-approved reincorporation in October 2007. They previously traded under the symbol PEP.AX. Please see the following for additional ASX information.
A. Peplin was founded in 1998 and reincorporated as Peplin, Inc. in 2007. Please see the Peplin history section for further details.
A. Peplin is headquartered in Emeryville, California, USA with offices in Brisbane, Queensland, Australia and manufacturing facilities in Southport, Queensland, Australia. Please contact us for further information.
A. Study results are published in ASX/media releases when data is available. Please sign up on Peplin's email list to automatically receive currently information about Peplin electronically. Alternatively, please see the Press releases section for all updates.
A. Please sign up on Peplin's email list to automatically receive Peplin financial information electronically. In addition, annual reports (for the year ended June 30), half yearly reports and select quarterly financial data are available online on the Reports to shareholders section of this website.
A. Peplin CDIs trade under the symbol PLI.AX after a shareholder-approved reincorporation in October 2007. They previously traded under the symbol PEP.AX. Historical prices can be found under the Share price information page.
A. Peplin does not pay dividends at this time.
A. Please refer to our Press releases section for Peplin's latest news and filings.
A. Please email or call your in-country office as per the Contact Us page.
Telephone: +1-800-881-5754
Email: peplin@medcomsol.com
Please refer to: www.clinicaltrials.gov for trial information
Email: info@peplin.com
6475 Christie Avenue
Suite 300
Emeryville, California 94608
Telephone: +1-510 653 9700
Facsimile: +1-510 653 9704
Level 2, Brisbane Portal
1 Breakfast Creek Road
Newstead
Brisbane, Queensland 4006
Telephone: +61-7-3250 1200
Facsimile: +61-7-3250 1299